Symbolbild · KI-generiert
Revive Therapeutics Ltd.
Stock factsheet
Company data from public sources (TMX Money, Canadian Securities Exchange, Nasdaq screener, Wikidata); every ISIN is verified against its check digit. Where „—“ appears, no verified value exists — we do not publish unverified identifiers. Market capitalisation is an order of magnitude as of the date shown, not a real-time figure. The size class follows the thresholds in common use (micro < $300m, small < $2bn, mid < $10bn) and is meant as an indication, not a definition.
Company profile
Revive Therapeutics is a life sciences company focused on the research and development of therapeutics and diagnostics for infectious diseases and rare disorders, and it is prioritizing drug development efforts to take advantage of several regulatory incentives awarded by the FDA such as Emergency Use Authorization, Orphan Drug, Fast Track, and Breakthrough Therapy designations. Currently, the Company is exploring the use of Bucillamine for the potential treatment of public health medical emergencies and rare inflammatory disorders. Revive is also advancing the development of Psilocybin-based therapeutics through various programs. For more information visit www.ReviveThera.com.
Company description as published by the issuer via Canadian Securities Exchange.
Comparable companies
Companies in the Biotech & Pharma sector of a similar size.
| Company | Ticker | Exchange | Market cap |
|---|---|---|---|
| Revive Therapeutics Ltd. | RVV | CSE | 7 Mio. USD |
| Captiva Verde Wellness Corp. | PWR | CSE | 8 Mio. USD |
| Marvel Biosciences Corp. | MRVL | TSXV | 7 Mio. USD |
| LIR Life Sciences Corp. | SKNY | CSE | 7 Mio. USD |
| PreveCeutical Medical Inc. | PREV | CSE | 7 Mio. USD |
| HYTN Innovations Inc | HYTN | CSE | 9 Mio. USD |
| AI-ML Innovations Inc. | AIML | CSE | 9 Mio. USD |
Investor Relations
We link only to primary sources from the company itself and from the regulators. Fields we have not recorded stay empty until a reliable source is available.
Information and education only — not investment advice, not a recommendation and not a financial analysis within the meaning of §85 WpHG or Art. 20 MAR. Investments in small and micro caps are highly speculative; total loss is possible. All information without warranty.